- Home
- LVO vs BCAB Comparison
LVO vs BCAB Comparison
Compare LVO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVO
- BCAB
- Stock Information
- Founded
- LVO 2009
- BCAB 2007
- Country
- LVO United States
- BCAB United States
- Employees
- LVO N/A
- BCAB N/A
- Industry
- LVO Restaurants
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- LVO Consumer Discretionary
- BCAB Health Care
- Exchange
- LVO Nasdaq
- BCAB Nasdaq
- Market Cap
- LVO 89.7M
- BCAB 101.0M
- IPO Year
- LVO N/A
- BCAB 2020
- Fundamental
- Price
- LVO $0.81
- BCAB $1.64
- Analyst Decision
- LVO Strong Buy
- BCAB Buy
- Analyst Count
- LVO 2
- BCAB 2
- Target Price
- LVO $2.75
- BCAB $5.00
- AVG Volume (30 Days)
- LVO 614.2K
- BCAB 914.1K
- Earning Date
- LVO 11-07-2024
- BCAB 11-07-2024
- Dividend Yield
- LVO N/A
- BCAB N/A
- EPS Growth
- LVO N/A
- BCAB N/A
- EPS
- LVO N/A
- BCAB N/A
- Revenue
- LVO $127,817,000.00
- BCAB $11,000,000.00
- Revenue This Year
- LVO $12.29
- BCAB N/A
- Revenue Next Year
- LVO $13.19
- BCAB N/A
- P/E Ratio
- LVO N/A
- BCAB N/A
- Revenue Growth
- LVO 17.10
- BCAB N/A
- 52 Week Low
- LVO $0.56
- BCAB $1.14
- 52 Week High
- LVO $2.15
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- LVO 49.40
- BCAB 38.66
- Support Level
- LVO $0.69
- BCAB $2.02
- Resistance Level
- LVO $0.95
- BCAB $2.53
- Average True Range (ATR)
- LVO 0.08
- BCAB 0.23
- MACD
- LVO 0.03
- BCAB -0.05
- Stochastic Oscillator
- LVO 58.24
- BCAB 0.56
About LVO LiveOne Inc.
LiveOne Inc, formerly LiveXLive Media Inc is a premium internet network devoted to live music and music-related video content. The company has been building an online destination for music fans to enjoy live performances from music venues and music festivals around the world, such as Rock in Rio, Outside Lands Music and Arts Festival, and Hangout Music Festival, as well as original content, artist exclusives, and industry interviews. The Company operates mainly through three segments, PodcastOne, Slacker, and Media Group, with a majority of its revenue derived from the Slacker segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.